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Cerebral ischemia is among the most common type of stroke seen in patient. Regeneration of death
neurons remains questionable. Human umbilical cord blood mononuclear cell (cbMNC) is one of the
treatment options for ischemia stroke through their various advantages; availability, pluripotency, and
immaturity. One group of healthy rats and three groups (n¼ 6 per group) of male Wistar rats undergone
permanent middle cerebral artery occlusion (MCAO). Rats were allowed to recover for 7 days before
intraarterial and intravenous injection of 1  106 cells/kg of human cbMNC. Behavioral tests were per-
formed before the MCAO, 1 week after MCAO, and at 3, 9, and 14 days after cbMNC injection. Brain infarct
area and neurons in hippocampus were evaluated. Spontaneous activity was much significantly
improved compared with the placebo group (p< 0.05). Comparing the neuron cells in hippocampus,
intraarterial and intravenous have more changes in neurons morphology. No effect of cbMNC implan-
tation in decreasing infarct area. Safety of xenogenic was confirmed by this study when the dosage of 1 
106 cells/kg was used and showed their beneficial effects.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Stroke is one of the commonest diseases with high mortality
and morbidity. Recently, the only treatment approved by the food
drug administration for acute ischemic stroke is thrombolysis, even
though this treatment has limited golden period. Thrombolysis
intravenously can be performed only in ischemic stroke where the
occlusion is not in the middle cerebral artery, and regeneration
therapy of death cells, unfortunately, remains questionable (Wei
et al. 2013; Shinozuka et al. 2013; Brouns et al. 2009).
Many studies have been conducted to show the effectiveness of
cell-based therapy by differentiating the route (intraarterial (IA),
intravenous (IV), and intraparenchyme)with result intraarterially is
more superior and safer compared with the other route. This hy-
pothesis arised because IA route showed larger amount of cells that
injected to the site of injury compared with IV route where thehdy).
nian Bogor.
ibuted equally to this work.
r. Production and hosting by Elspossibility of cells to enterapt in the lung was higher and they must
be passing through peripheral organs, and the cell amount would
be less in the site of injury as consequences (Guzman et al. 2008).
From previous studies, cell-based therapy for ischemic stroke,
where cord blood mononuclear cell (cbMNC) was used, showed
positive results in functional assessment by decreasing apoptosis,
inflammation in periinfarct area, and stimulate angiogenesis,
whether it was given intraarterially, intravenously, or intra-
parenchymally. First and second phase of the study have shown
that the injection of stem cells for acute and subacute ischemic
stroke was safe (Fruchtman et al. 2004).
The source of cell itself is another problem to be solved. The past
two decades have shown significant progress in basic under-
standing of adult stem cells biology. Cells derived from the human
umbilical cord have been successfully used in the clinic for almost
two decades (Hows et al.1992; Gluckman et al. 1989; Locatelli et al.
2003; Rocha et al. 2001). Their simple and economic retrieval,
enrichment for hematopoietic progenitors, enhanced proliferation
rate, expansion potential (Lewis et al. 2000; Ringden et al. 2008),
and low incidence of graft-versus-host disease (Harris et al. 2009;
Rocha et al. 2004) make them a promising cell treatment forevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Y. Ramli, et al188neurological diseases. Although their therapeutic benefits were
initially thought to be limited to hematopoietic disorders, several
recent studies have shown the potential of these human umbilical
cordederived cells to enhance regeneration and tissue repair in
various pathological disorders, including neurologic diseases
(McGuckin et al. 2006; Rosenkranz et al. 2011).
Various study methodology play an important role because of
different route, dosage, time to inject, and the origin stem cells
whether from human cord matrix or cord blood are used could
make different results. The other advantage of cbMNC is their
pluripotency by having a heterogenous mix of immature lympho-
cyte, monocyte (Sorg et al. 2001; Yang et al. 2010), hematopoietic
(Mayani et al. 1998), endothelial (Ingram et al. 2004), and mesen-
chymal (Erices et al. 2000; Flynn et al. 2007; Lee et al. 2004; Secco
et al. 2008) stem/progenitor cells.
All the cells derived from cbMNC have their contribution to the
neurogenesis and angiogenesis. Neurogenesis could be stimulated
by inducing endogenous stem cells in subgranular zone, sub-
ventricular zone, and subcortical area (Altman et al. 1963; Eriksson
et al. 1998; Kokaia et al. 2013). Angiogenesis and neurogenesis is
something that could not be separated, where angiogenesis could
stimulate neurogenesis and helping migration of progenitor cells to
the periinfarct site (Kojima et al. 2010).
2. Materials and Methods
2.1. Permanent middle cerebral artery occlusion model
One group of healthy rats and three groups (n ¼ 6 per group) of
250e300 g of male Wistar rats undergone permanent middle ce-
rebral artery occlusion (MCAO), where group 2 was treated with
physiological fluid intraarterially, group 3 with cbMNC intra-
arterially, and group 4 with cbMNC intravenously. Behavioral tests
were performed before the MCAO, 1 week after MCAO, and at 3, 9,
and 14 days after cbMNC injection. Brain infarct area, neurogenesis
in hippocampus, and neovascularization in infarct area were eval-
uated. One week after occlusion, rats were injected by cbMNC withRats treated with mid
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Figure 1. Stud1 106 cells/kg that has been characterized by cd34þ (7%) intra-
arterially and intravenously. Two weeks after implantation, all rats
were euthanized and functional assessment in day 3, 9, and 14 after
implantation were evaluated. Histopathology confirmation by he-
matoxylin eosin (H&E) and cresyl violet staining were marked
(Hunter et al. 2000; Lubjuhn et al. 2009; Rosell et al. 2013)
(Figure 1).2.2. cbMNC isolation
Cord blood sample obtained from cryopreservation was not
used by the Cellsafe International Corporation. All cord blood units
tested negative for human immunodeficiency virus, hepatitis C
virus, hepatitis B virus, human T-cell lymphotropic virus, and
syphilis. Cord blood suspension was processed using gradient
centrifugation method as follows: Use aseptic technique proced-
ures and biosafety cabinet operation. Cryopreserved cord blood
samples were thawed and washed using PBS and centrifuged at
1500 rpm for 10 minutes. Washing was done two times. Ficoll-
Paque solutionwas put in 15 mL tube. Pipette carefully the cleaning
results of cord blood into a tube containing Ficoll-Paque. The vol-
ume ratio of bone marrow suspension: Ficoll-Paque¼ 1:1. Centri-
fugation was performed at 2200 rpm for 10 minutes at 20C,
centrifugation termination did not use brakes (to prevent disor-
ganization of fractions of separate components). Buffy coat layer
(the layer contains nucleated cells) was taken using a pipette slowly
and transferred to a 15-mL centrifuge tube. Clean the buffy coat of
erythrocytes using lysis buffer as much as 3mL. Clean the buffy coat
of lysis buffer using NaCl as much as 4 mL, and the number of cells
was counted with a counting chamber and trypan blue staining.2.3. Implantation of cbMNC procedures
On the 7th day after ischemia condition, the experimental ani-
mals were randomly assigned and received a transplant of 1 106
cells/kg of cbMNC in 1 mL of fluid. In the group treated with im-
plantation intravenously, cbMNC was inserted slowly through
the tail vein of rats. In the group treated with implantationdle cerebral artery occlusion        
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Cord blood mononuclear cells for brain ischemic 189intraarterially, cbMNC was slowly inserted through the common
carotid artery on the contralateral side by using a 32 gauge size
needle.2.4. Assessment of neurologic deficit
Clinical experimental animals were assessed by a cylinder test
and latency to move tests (spontaneous activity). Evaluation was
assessed before theMCAO, 7 days after occlusion, and at 3, 9, and 14
days after implantation. Cylinder test, in this test, rats were put in
glass cylinder tube of 9e10 cm diameter and 15 cm height. Rat will
put the limb in a glass tube vertically. Analyzing the results of the
test was done by recording and observing which limb was more
dominant in contact with the tube. Formula score of asymmetry
extremity use¼ Ipsilateral/(Ipsilateral þ Contralateral þ Both) 
Contralateral/(Ipsilateral þ Contralateral þ Both) (Balkaya et al.
2013; Hunter et al. 2000; Zarruck et al. 2011). Latency to move
test was performed to evaluate the spontaneous activity. The
advantage of this technique is easy to perform by putting a rat in a
cage (glass box) and count the time the rat takes to move as far as
its body length (7 cm) and recorded (Lubjuhn et al. 2009; Rosell
et al. 2013).2.5. Histopathological confirmation of infarct area and
neurons in hippocampus
On day 21 after the MCAO or 14 days after implantation, the
experimental animals were euthanized, perfused transcardially
with PBS (pH 7.4) followed by 10% buffered formalin. Brains of
experimental animals were taken and cut serially between þ1
to 1 bregma with three coronal sections (2 mm apart). One
coronal section behind bregma (5 mm) was stained with cresyl
violet. ImageJ software by the National Institutes of Health was
used to measure the total ipsilateral, contralateral, and infarct
areas. Infarct area was calculated by using the following for-
mula: infarct size¼ 100  [total contralateral hemisphere area 
(total ipsilateral hemisphere area  infarct area)/total contra-
lateral hemisphere area] (Chen et al. 2001; Vendrame et al.
2004). We also calculated the neurons in hippocampus area
(Ca1, Ca3, and dentate gyrus). One coronal section in front of
bregma was stained by H&E. Preparation was observed by light
microscopy and photographed using 400 magnification (Nikon
Corporation, Nikon Eeclipse TE 2000-U, Tokyo, Japan) in five
visual fields with a consistent location. MCAO      Implanta?on 
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Figure 2. cbMNC intraarterial and intravenous in promoting motor coord2.6. Data processing
Data were analyzed using the Statistical Product and Service
Solution (SPSS), IBM Corporation, SPSS Statistics, Version 20.0, New
York, US. After normalizing the data, one-way analysis of variance
was performed in histopathology evaluation. KruskaleWallis
analysis was done when the data were not distributed normally.
Behavioral evaluations were analyzed using two-way analysis of
variance between the periods of time in each group, and least
significant difference (LSD) post-hoc analysis was performed when
there was a significant difference between groups.
2.7. Research ethics
This research has been approved by the research ethics of
medicine/health Medical Faculty of Universitas Indonesia.3. Results
3.1. cbMNC IA and IV in promoting motor coordination
Before surgery on rats, all groups showed a balanced use of
extremity and no significant difference (p> 0.05). After the MCAO,
there were differences in using their extremity, which in the pla-
cebo and treatment groups (3 and 4) used the extremity that was
not paralyzed more often than the healthy group (p< 0.05). Three
days after implantation, significant differences were not found
statistically between groups with p> 0.05. On day 9 after implan-
tation, there were significant differences between group 3 and
other groups with p< 0.05. The third group showed no improve-
ment at day 3 or 9 after implantation, but showed positive
improvement at 14 days after implantation. Nevertheless, in group
4, at 3 days after implantation obtained better improvement than
the groups 2 and 3 (Figure 2).
3.2. cbMNC IA and IV promote improvement in spontaneous
activity
In the analysis of spontaneous activity, significant differences
occurred at day 7 after occlusion, 3, 10, and 14 days after implan-
tation. A significant difference was found in all groups compared
with the normal group (p< 0.05). Seeing an existing chart
(Figure 2), it is clear that occlusion slowed down spontaneous ac-
tivity in placebo and treatment groups. Before implantation, pla-
cebo group did not showed any improvement until the end of the
evaluation day (14 days after implantation). On the other hand,
treatment group showed good improvement that close to the value
before occlusion with p< 0.05 compared with placebo.D 10 D 16 D 21   
est
MCAO+ cbMNC IA MCAO+ cbMNC IV
ination. IA¼ intraarterial; MCAO¼middle cerebral artery occlusion.
Table 1. The ratio of death cells in the cortex area
Group Total Mean p-Value
1 (Negative control) 6 0.36± 0.03 0.028y
2 (Placebo intraarterial) 6 Minimum: 0.28
Maximum: 0.46*
3 (Intraarterial) 6 0.66± 0.06
4 (Intravenous) 6 0.47± 0.11
* Group 2 distribution was abnormal, but overall distribution was normal.;
y Using one-way analysis of variance with post-hoc LSD significant groups of 1
and 3, groups 2 and 3.
Y. Ramli, et al1903.3. Evaluation of the effect of cord blood mononuclear cell
implantation histopathologically
3.3.1. Infarct area reduction
Staining with cresyl violet was used and evaluated quantita-
tively using the ImageJ software with the following formula:
infarction area¼ 100 [total area contralateral hemisphere (total
area ipsilateral hemisphere  infarcted area)/total area hemi-
spheric contralateral] (Chen et al. 2001; Vendrame et al. 2004). One
sample was taken from groups 2, 3, and 4 which represented
qualitatively. Area taken in this measurement was a coronal slice
1 from bregma with 5 mm thickness. In group 2, area infarction
was obtained at 15% wide. Compared with treatment groups 3 and
4, the area of infarction was not reduced and tend to be more,
where the infarcted area in group 3 amounted to be 22% and 18% in
group 4 (Figure 3).
To ensure quantitatively, the ratio of death neuron cells was
calculated with the following formula: ratio of death cells¼ death
cells/(death cells þ living cells), which were compared between
groups. The calculation of the number of neurons in the cortex area
was using H&E staining with a consistent location on each group in
five visual fields with a consistent location (Table 1).
3.3.2. Neurogenesis in hippocampus area
In evaluating neurogenesis in the hippocampus as the effect of
implantation, the number of neuron cells were compared between
groups. Qualitatively, the changes in morphology of neuron cells
were also noticed. The calculation in the hippocampus area was
counted on three different zones, namely Ca1, Ca3, and dentate
gyrus with 400magnification (Figure 4). It showed that groups 3
and 4 have more neuron cells in hippocampus area compared with
group 2 with p> 0.05 (Table 2).
4. Discussion
Based on studies, implantation intraarterially in rat with MCAO
obtained cells at the infarct area more than in IV (Li et al. 2001; Li
et al. 2002; Harting et al. 2009). Given the evidence of the exis-
tence of cells that reach the infarct lesion then functional
improvement can occur with paracrine effects possessed by these MCAO 
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Figure 3. cbMNC intraarterial and intravenous promote improvement in spontaneous
MCAO¼middle cerebral artery occlusion.cells to stimulate endogenous stem cells to be more active in
neurogenesis and angiogenesis. The treatment group of rats
implanted with cbMNC both intravenously and intraarterially
experienced improvement in spontaneous activity. There is an
involvement of cognitive, spatial learning, andmemory function for
rats to do spontaneous activity. Therefore, neurogenesis in hippo-
campus area is needed to be evaluated, because functions are
controlled by hippocampus.
Neurogenesis occurs in the hippocampus or subgranular zone
(SGZ) have more impact on processes such as learning, memory,
and cognitive (Marlier et al. 2015). Adult hippocampal neurogenesis
generates new excitatory granule cells in the dentate gyrus, whose
axons form the mossy fiber tract to CA3 (Kempermann G et al.
2015). The connection between dentate gyrus, CA3, and CA1 is
interconnected by trisynaptic circuit, and Becker considers neuro-
genesis in a model of the full hippocampal loop (entorhinal cor-
texedentate gyruseCA3eCA1eentorhinal cortex; Becker 2005).
Moreover, the neuroanatomy of dentate gyrus predicts that it
carries out a specific information-processing task that receives
from the entorhinal cortex and conveys to the area CA3, where they
terminate in large synapse- and interneuron-rich structures, the so
called “boutons.” They also provide excitatory input to the pyra-
midal cells of CA3.
Adult neurogenesis within the hippocampus is mainly observed
in SGZ of dentate gyrus, where it consists of several developmental
stages that are characterized by different morphology. Radial glia-
like precursor cells are the cell where adult hippocampal neuro-
genesis originates from where cell belonging to type 1 that areD 10 D 16 D 21
s ac?vity
CAO+cbMNC IA MCAO+cbMNC IV
P<0.05 
activity. cbMNC¼ cord blood mononuclear cell; IA¼ intraarterial; IV¼ intravenous;
Figure 4. Effect of cbMNC implantation with cresyl violet staining in infarct and hippocampus area. (A) Infarct area in the cortex, that magnified with 400 magnification (within
the same area). Black circle marked the death neurons in the cortex. (B) Neuron cells in CA1, (C) CA3, and (D) dentate gyrus. It showed that the number of neuron cells was higher in
IA compared with IV and placebo group. Black arrows showed morphology variance changes in neuron cell-shaped that indicates proliferative activity and turnover of the neurons
where in IA group was way faster compared with IV and placebo group qualitatively, especially in dentate gyrus and CA3, but not in CA1. Scale bar¼ 50 mm. cbMNC¼ cord blood
mononuclear cell; IA¼ intraarterial; IV ¼ intravenous.
Cord blood mononuclear cells for brain ischemic 191abundant within SGZ and have astrocytic properties and express
glial fibrillary acidic protein (GFAP). To understand the complex
multistep processes of neurogenesis, variable marker can be used.
The limitation in this study is we did not characterize by any
markers to determine if they were CA1 or CA3 pyramidal cells or
dentate granule cells. This remains to be performed in future
studies. By using morphological changes that are seen in hippo-
campus, we suggest that the process of neurogenesis is ongoing.
Morphology of the cells have their own characterization, where
type 1 cells are characterized by triangular shaped and the apicalprocess extend toward the molecular layer of dentate gyrus. From
type 1 cells, it will give rise proliferate the intermediate precursors
and generate new type 2 cell that is characterized by a small soma,
irregular shaped nucleus, and short and horizontally oriented
processes (Ehninger & Kempermann 2008; Kempermann G et al.
2004). Type 3 cells are in a transition phase from neuroblast to
the postmitotic immature neuron and enter a maturation stage,
where they extend their dendrite into the molecular layer and the
axon to CA3. Under physiological conditions, they have little pro-
liferative activity, but under pathological conditions, they can
Table 2. Effect of cord blood mononuclear cell on neurogenesis in hippocampus area
Group No Dosage Ca1 (mean) Ca3 (mean) Dentate gyrus (mean) Hippocampus (mean) p-Value
1 (Negative control) 6 e 201.00± 55.79 121.66± 27.65 297.33± 15.62 206.66± 12.86 <0.001
2 (Placebo intraarterial) 6 e 99.50± 60.14 84.33± 21.69 153.67± 36.22 111.99± 33.64
3 (Intraarterial) 6 1  106 cells/kg 112.83± 36.42 103.83± 16.25 153.33± 37.69 123.33± 20.65
4 (Intravenous) 6 1  106 cells/kg 104.83± 30.07 97.33± 22.12 157.50± 35.41 119.88± 18.66
Y. Ramli, et al192increase their proliferative activity. The morphology of type 3 cells
is highly variable, but the orientation of the process changes from
horizontal to vertical (Kempermann G et al. 2011).
Furthermore, neurogenesis in the dentate gyrus appears to be
under environmental control, modern stereological studies have
shown that the total number of granule cells does not vary in adult
animals, and we found there were no significant differences in the
number of cells in hippocampus area. This implies that there is a
steady-state turnover of granule cells rather than a continuous
accretion (Desmond N. 1985). Indeed, we found that many changes
in morphology of the cells in hippocampus area qualitatively,
especially in dentate gyrus. Thus, findings may suggest that the
cbMNC stimulated the turnover of the cells and induced the pro-
liferative of neurons activity. Based on time course, we evaluated
that the neurogenesis process was 3 weeks after transplantation
and it has been estimated that entire period of adult neurogenesis
takes about 7 weeks. The speed of maturation and proliferative
activity might differ under pathological conditions and external
stimulation (Kempermann G et al. 2015). Therefore, we suggest that
during 3 weeks after implantation, process of neurogenesis is going
on even though maturation of the new neurons may not under
complete process of maturation. By comparing the placebo and
cbMNC groups, it showed different morphology of neurons in
hippocampus, especially in dentate gyrus and CA3, but not in CA1.
In contrast to information transfer from CA3 to CA1, the connec-
tions betweenpyramidal neurons are individuallyweak; and unlike
CA3, CA1 contains very few recurrent connections (Bolshakov &
Siegelbaum 1995). Based on this result, we suggest cbMNC im-
plantation could induce the proliferative activity and turnover the
neurons. However, the number of neuron cells were also higher
within hippocampus area in cbMNC groups and it may be the result
from neuroprotective effect of cbMNC (Greggio et al. 2014;
Madeddu et al. 2004; Wang et al. 2012). This is consistent with
the results obtained either functionally or quantitatively in this
research.
Unfortunately, in sensory motor function by using cylinder test,
the results were very difficult to be used as a benchmark of cbMNC
effect. In the placebo group, it turned out to show improvement
even without administration of cbMNC. From the previous studies,
it was reported that cylinder test may reach the average improve-
ment after 1e2 weeks of occlusion (Balkaya et al. 2013; Hunter et al.
2000; Zarruck et al. 2011). Nevertheless, when we evaluated the
Figure 1, even though IA group did not make the improvement as
fast as IV group, at the end of the evaluation day, the trend showed
positive results. Nevertheless, IV group showed a fluctuative graph
after their improvement at day 3 postimplantation, even though it
regained positive result at the end of the day. Based on this result,
because IA cbMNC will reach faster in the higher amount to the
brain area compared with IV, we hypothesize that may be inflam-
matory factors surged after the implantation that may affect the
outcome. After some time, thus inflammatory factors reduced and
improvement achieved. On the other hand, there were no cells
administered in placebo group, therefore fluctuative graph was not
appeared. Moreover, in previous studies, IL6, ILB, and TNF alpha
cytokines reached their peak on day 7 postischemia and declined at
day 14, and in the administration of cbMNC, there was anonsignificant decrease of those cytokines, thereby cbMNC capa-
bilities in delivering more improvements to its effect in removing
growth factors that can reduce oxidative stress (Karlupia et al.
2014). Unfortunately, we did not evaluate further which inflam-
matory factors that appeared after implantation of cbMNC, because
inflammation factors were not the aim of our study and this hy-
pothesis need to be investigated further.
Anti-inflammatory and growth factors such as vascular endo-
thelial growth factor (VEGF) and brain-derived neurotrophic factor
(BDNF) is one of the pluripotency that cbMNC has (Ergul et al.
2012), where BDNF if given in IV can reduce infarct area and me-
diates existing vascular endothelial cell proliferation, migration of
neuronal cells, and modulate synapse function (Karlupia et al.
2014). In this study, we failed to show a reduction in infarct area
(Makinen et al. 2006; Zawadska et al. 2009). These results provide
question whether the dose given quite optimal or required evalu-
ation in a longer time before euthanized the rats to allow new
neuron cells to be migrated to infarct area? These results also gave
different results to studies that have been done before, where the
effective results obtained if given before 48 hours post-MCAO
(Newcomb et al. 2009). There was possibility that gliosis has
occurred and established, because we implanted the cells in sub-
acute period.
In previous studies, CD34þwas given in a large number, but we
delivered only 7% of CD34þ to see the effect of pluripotency of
cbMNC (Deepti et al. 2009; Ergul et al. 2012). Human CD34þ cells
were shown to secrete numerous angiogenic factors, including
VEGF, HGF, and IGF-1 and as a potent regulator of adult neuro-
genesis (Taguchi et al. 2004). In experiments with experimental
animal performed by Ohtaki et al. (2006), it was reported that on rat
after the occlusion and ischemia occurred, a positive reaction for
VEGF increases along time. In this study, vascularization appeared
more visible in periinfarct area in groupwas administered by IA and
IV route compared with placebo qualitatively (Figure 5).
The cbMNC xenogenic implantation also known can stimulate
the body's immune response, even at dosage below 5  106 cells
was still safely administered and does not causemortality (Karlupia
et al. 2014), although immunosuppression was not given which
may be neuroprotective so that will give bias outcome (Kaminska
et al. 2004; Saino et al. 2010). In addition, cbMNC has a high per-
centage in the levels of T lymphocytes regulation (Tregs) than in the
peripheral blood. Tregs are known to have the ability to boost the
immune system and anti-inflammatory that can be neuro-
protective post stroke (Liesz et al. 2009). In addition, Tregs also has
the ability to reduce the incidence of graftehost reaction (Brunstein
et al. 2011).Therefore, there was no mortality of rats after implan-
tation in this study, even though we did not evaluate the level of
Tregs.
In recent decades, many translational researcheswith cell-based
therapy was performed and produced a very good progress for the
future in understanding the basic effect of stem cells in ischemic
stroke. This study proved the administration of cbMNC both in IA
and IV with doses of 1  106 cells/kg showed improvements in
spontaneous activity. Histopathologically, cbMNC implantation by
IA could induce the proliferative activity and make the turnover of
neurons faster compared with IV and placebo. The number of the
Figure 5. Staining hematoxylin eosin (H&E) with 400 magnification in ipsilateral cortex area: (A) placebo group obtained vessels (black arrow) that formed fewer in periinfarct
area compared with group IA (B) and IV (C). Scale bar¼ 50 mm. IA¼ intraarterial; IV¼ intravenous.
Cord blood mononuclear cells for brain ischemic 193neuron cells was also higher, although statistically not significant
within hippocampus area in cbMNC groups and it may be the result
from neuroprotective effect of cbMNC. In addition, the IA admin-
istration showed the presence of more vascularization than IV and
placebo, although the existing CD34þ is only 7% and it may
confirm the pluripotency effect of cbMNC. On the other hand, the
improvement of sensory motor function and reduction of infarct
area did not show satisfactory results, it may be due to (1) dose
given was not optimal, (2) timing of implantation need to be
reconsidered, and (3) long-term evaluationwas required to provide
the opportunity for new neurons to migrate to the periinfarct area.
This study also proved the absence of xenograft implantation
rejection reactions in both IA and IV cbMNC with a dose of 1 106
cells/kg.
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